In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans
about
Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicansSynergy of nitric oxide and azoles against Candida species in vitro.NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised LearningStatins, bugs and prophylaxis: intriguing possibilities.Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole.Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery.Inhibition of Candida albicans by Fluvastatin Is Dependent on pH.Mevalonate governs interdependency of ergosterol and siderophore biosyntheses in the fungal pathogen Aspergillus fumigatus.Atorvastatin Reduces the Survival of Candida albicans-Infected BALB/c Mice.Antibacterial activity of extracellular compounds produced by a Pseudomonas strain against methicillin-resistant Staphylococcus aureus (MRSA) strains.Statin Concentrations Below the Minimum Inhibitory Concentration Attenuate the Virulence of Rhizopus oryzaeSynergistic efficacy of Bisbenzimidazole and Carbonyl Cyanide 3-Chlorophenylhydrazone combination against MDR bacterial strains.Antibacterial synergic effect of honey from two stingless bees: Scaptotrigona bipunctata Lepeletier, 1836, and S. postica Latreille, 1807.Synergistic and Additive Effect of Oregano Essential Oil and Biological Silver Nanoparticles against Multidrug-Resistant Bacterial Strains.Synthetic arylquinuclidine derivatives exhibit antifungal activity against Candida albicans, Candida tropicalis and Candida parapsilopsis.Honey Antibacterial Effect Boosting Using Origanum vulgare L. Essential Oil.
P2860
Q28082407-DD6F1B2F-E8C5-4C09-8A81-C811B216F7C9Q28368892-F79829E6-A93C-4FDF-B222-1E598E535A5AQ28552626-7458AEA4-ED8E-41F2-82E0-286DDA110E26Q30357923-5E9060B8-366E-48AB-9B0A-234DB8235412Q34301592-9DE5E3A4-5538-4F0C-8E69-A8FFE580480CQ34374275-EC14B9A3-4461-4DA0-BE83-440B82938118Q34423788-D384C912-BD32-415E-9C18-698AB5A3C3A9Q35779263-0B0A2F3B-4542-4894-97BF-7D843492C638Q36392153-9511F4B9-3A11-48BB-A82E-82598EE14F84Q36964585-64BB34A2-0415-4F4A-90D4-78E762FB9A89Q37223743-89C87471-2B23-4E9E-AF66-47C184B47404Q37707919-12C58650-0761-41FC-80E3-BB6147E372E6Q38380313-CF6F7DAB-D55E-46CD-885C-737747751D32Q40652529-869D917B-2D01-4787-8E72-E57C476A28F0Q42255891-FB0D10DC-8F1E-435C-87C2-2E5ADAF17279Q54969752-DFA8F5AC-9B68-46F1-AC83-696733C9C3A1
P2860
In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans
description
1997 nî lūn-bûn
@nan
1997 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
In vitro activity of fluvastat ...... es and Cryptococcus neoformans
@ast
In vitro activity of fluvastat ...... es and Cryptococcus neoformans
@en
In vitro activity of fluvastat ...... es and Cryptococcus neoformans
@nl
type
label
In vitro activity of fluvastat ...... es and Cryptococcus neoformans
@ast
In vitro activity of fluvastat ...... es and Cryptococcus neoformans
@en
In vitro activity of fluvastat ...... es and Cryptococcus neoformans
@nl
prefLabel
In vitro activity of fluvastat ...... es and Cryptococcus neoformans
@ast
In vitro activity of fluvastat ...... es and Cryptococcus neoformans
@en
In vitro activity of fluvastat ...... es and Cryptococcus neoformans
@nl
P2093
P2860
P3181
P1476
In vitro activity of fluvastat ...... es and Cryptococcus neoformans
@en
P2093
I Weitzman
P Della-Latta
P2860
P3181
P407
P577
1997-04-01T00:00:00Z